Intracranial Aneurysms Managed by Parent Artery Reconstruction Using Tubridge Flow Diverter study: 1-year outcomes

医学 分流器 动脉瘤 放射科 外科
作者
Qiang Li,Nan Lv,Li Li,Yuxiang Gu,Liquan Xu,Ming Lv,Changren Huang,Guohua Mao,Hua Lu,Shu Zhong,Chuan‐Zhi Duan,Xiaodong Xie,Jieqing Wan,Feng Wang,Sheng Guan,Rui Zhao,Dongwei Dai,Yu Zhou,Qinghai Huang,Yi Xu
出处
期刊:Journal of Neurosurgery [American Association of Neurological Surgeons]
卷期号:141 (6): 1697-1704 被引量:9
标识
DOI:10.3171/2024.3.jns232116
摘要

OBJECTIVE: Previous randomized controlled trials have reported a significantly higher occlusion rate of large and giant aneurysms when utilizing the Tubridge flow diverter (FD). In the present trial, the safety and efficacy of the Tubridge FD in treating unruptured internal carotid artery (ICA) or vertebral artery (VA) aneurysms were assessed in a real-world setting. METHODS: The Intracranial Aneurysms Managed by Parent Artery Reconstruction Using Tubridge Flow Diverter (IMPACT) study is a prospective, multicenter, single-arm clinical trial assessing the efficacy of the Tubridge FD in the management of unruptured aneurysms located in the ICA or VA. The primary endpoint was the complete occlusion (Raymond-Roy class 1) rate at the 1-year follow-up. The secondary endpoints included the technical success rate, the successful occlusion rate of the aneurysm, which is the degree of aneurysm embolization scored as Raymond-Roy class 1 or 2, major (> 50%) in-stent stenosis, and incidence of disabling stroke or neurological death associated with the target aneurysms. RESULTS: This study included 14 interventional neuroradiology centers, with 200 patients and 240 aneurysms. According to angiographic core laboratory assessment, 205 (85.4%) aneurysms were located in the ICA, 34 (14.2%) in the VA, and 1 (0.4%) in the middle cerebral artery. Additionally, 189 (78.8%) aneurysms were small (< 10 mm). At the 12-month follow-up, the total occlusion rate was 79.0% (166/210, 95% CI 72.91%-84.34%). Additionally, the occurrence of disabling stroke or neurological death related to the specified aneurysms was 1% (2/200). CONCLUSIONS: The 1-year results from the IMPACT trial affirm the safety record of use of the Tubridge FD in the treatment of intracranial aneurysms in real-world scenarios. These results reveal low morbidity and mortality rates of 3.5% and 1.5%, respectively. Furthermore, they provide evidence of the effectiveness of the Tubridge FD, as demonstrated by the complete occlusion achieved in 166 of 210 (79%) cases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zz完成签到,获得积分10
3秒前
眨眼完成签到,获得积分10
5秒前
baishuo完成签到,获得积分10
5秒前
Nole应助冷静的代荷采纳,获得10
6秒前
sunny完成签到,获得积分10
6秒前
无情的聪健应助Cindy采纳,获得20
7秒前
Lucas应助456qwe采纳,获得10
7秒前
楠木木完成签到 ,获得积分10
8秒前
Sun1c7完成签到,获得积分10
8秒前
yupeng_xu完成签到 ,获得积分10
12秒前
SciGPT应助天天向上采纳,获得10
12秒前
喜庆完成签到,获得积分10
13秒前
李重坤完成签到,获得积分10
13秒前
菌匠完成签到 ,获得积分10
13秒前
shetianlang完成签到 ,获得积分10
14秒前
矮小的柠檬完成签到,获得积分10
15秒前
luoyaw完成签到 ,获得积分10
15秒前
愉快的烤鸡完成签到,获得积分10
16秒前
19秒前
yyy完成签到,获得积分10
20秒前
勋章完成签到 ,获得积分10
20秒前
dd36完成签到,获得积分0
20秒前
wmbgmt完成签到,获得积分10
21秒前
WZZ完成签到,获得积分10
23秒前
SuperbangGGG完成签到,获得积分20
24秒前
文献高手完成签到 ,获得积分10
26秒前
26秒前
27秒前
王博完成签到,获得积分10
28秒前
yanyue完成签到 ,获得积分10
29秒前
Lucas应助prof.zhang采纳,获得10
29秒前
天天向上发布了新的文献求助10
31秒前
32秒前
粗暴的醉卉完成签到 ,获得积分10
32秒前
等风的人发布了新的文献求助10
33秒前
开朗的爆米花完成签到 ,获得积分10
36秒前
星星完成签到 ,获得积分10
37秒前
SuperbangGGG关注了科研通微信公众号
38秒前
1117发布了新的文献求助10
38秒前
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Periodic Report Summary 2 - AFTER (A Framework for electrical power sysTems vulnerability identification, dEfense and Restoration) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7318637
求助须知:如何正确求助?哪些是违规求助? 8934368
关于积分的说明 18938693
捐赠科研通 6977413
什么是DOI,文献DOI怎么找? 3214255
关于科研通互助平台的介绍 2382220
邀请新用户注册赠送积分活动 2193235